Hansoh Pharmaceutical Group Company Limited
Research Hansoh Pharmaceutical Group Company Limited (3692.HK) on Bullrun: market cap HKD 192.43B, P/E 25.8, dividend yield 1.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3692.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 192.43B
- P/E25.8
- Dividend yield1.4%
- Financial periodFY2025
- RevenueCNY 15.03B
- Revenue growth22.6%
- Net incomeCNY 5.56B
- Free cash flowCNY 6.25B
- Gross margin90.0%
Valuation Snapshot
latest market cap is HKD 192.43B; P/E is 25.8; dividend yield is 1.4%.
Peer valuation comparison
Latest P/E is 25.8x versus a Healthcare sector median of 21.69x (19.0% above).
Latest dividend yield is 1.41% versus a Healthcare sector median of 2.41% (41.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 15.03B | CNY 5.56B | CNY 6.25B | 90.0% | 0.93 | CNY 31.55B | CNY 105.09M | CNY 35.36B |
| FY2024 | CNY 12.26B | CNY 4.37B | CNY 3.34B | 91.0% | 0.73 | CNY 22.62B | CNY 117.89M | CNY 28.68B |
| FY2023 | CNY 10.10B | CNY 3.28B | CNY 2.75B | 89.8% | 0.52 | CNY 22.43B | CNY 4.30B | CNY 25.79B |
| FY2022 | CNY 9.38B | CNY 2.58B | CNY 2.45B | 90.8% | 0.44 | CNY 17.62B | CNY 4.38B | CNY 22.65B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 192.43B | 25.8 | 1.5% | 0.49 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.49 HKD, yield 1.4%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.37 CNY |
| FY2024 | 0.34 CNY |
| FY2023 | 0.12 CNY |
| FY2022 | 0.14 CNY |
About Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan;
ETFs that hold Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| VanEck New China ESG UCITS ETF | 1.10% | 0.60% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hansoh Pharmaceutical Group Company Limited's market cap?
Hansoh Pharmaceutical Group Company Limited's market capitalization is HKD 192.43B.
What is Hansoh Pharmaceutical Group Company Limited's P/E ratio?
Hansoh Pharmaceutical Group Company Limited's price-to-earnings (P/E) ratio is 25.8.
Does Hansoh Pharmaceutical Group Company Limited pay a dividend?
Hansoh Pharmaceutical Group Company Limited has a dividend yield of 1.4%.
What does Hansoh Pharmaceutical Group Company Limited do?
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases.